Accelerated progression relapse test



An Accelerated Progression Relapse Test (APRT) and method is provided for use in the prognosis of a patient having an ER+ breast cancer. The APRT provides a determination of when a patient in a particular diseased state is likely to benefit from further disease treatment, or does not have a high probability of benefit with additional treatment. Four genetic probes are disclosed that target the MKI67, CDC6 and SPAG5 gene and gene products. The ER+ breast cancer patient population is stratified into two groups, with the low gene expression group identifying the patient/patient group that is less likely to benefit from additional treatment measures, and a high gene expression group identifying the patient group that is more likely to benefit from additional treatment measures.


Attribute NameValues
  • Accelerated progression relapse test

Patent Number
  • US 9721067 B2

  • Steven Buechler

Inventor From Local Institution
  • Steven Buechler

Other Application
  • 42227604

Prior Publication Date
  • 2016-12-29

  • 2015-05-07

Prior Publication Number
  • US 20160378934 A9

  • 13

Cooperative Patent Classification codes
  • C12Q 1/6886 (20130101); G01N 33/57415 (20130101); G06F 19/20 (20130101); G06F 19/345 (20130101); C12Q 2600/106 (20130101); C12Q 2600/158 (20130101); G01N 2800/56 (20130101); G06F 19/24 (20130101); G01N 2800/52 (20130101)

International Patent Classification codes
  • G01N 33/53 (20060101); C12Q 1/68 (20060101); G06F 19/00 (20110101); G01N 33/574 (20060101); G06F 19/20 (20110101); G06F 19/24 (20110101)

  • English

Date Issued
  • 2017-08-01

  • U.S. Patent and Trademark Office

  • University of Notre Dame du Lac

Record Visibility Public
Content License
  • All rights reserved

Departments and Units
Member of


Collections Featuring this Patent
Notre Dame Patents


Please Note: You may encounter a delay before a download begins. Large or infrequently accessed files can take several minutes to retrieve from our archival storage system.